Chikungunya in Latin America (2020–2025): Epidemiological Burden, Clinical Impact, and Public Health Priorities
DOI:
https://doi.org/10.70099/BJ/2025.02.04.16Keywords:
Chikungunya virus, Latin America, arboviruses, Aedes aegypti, Aedes albopictus, epidemiology, chronic arthropathy, public health, vector-borne diseases, surveillanceAbstract
Chikungunya virus (CHIKV) has maintained sustained transmission in Latin America since its introduction in 2013, generating recurrent outbreaks and a significant clinical, social, and economic burden. Between 2020 and 2025, more than 2.8 million suspected cases were reported, with Brazil contributing the highest morbidity and disability-adjusted life years (DALYs). Acute infection is characterized by sudden-onset fever, severe polyarthralgia, myalgia, headache, and a maculopapular rash. Approximately 40% of patients develop chronic arthropathy, which may persist for months or years, affecting functional capacity and quality of life. The diagnostic accuracy is challenged by the co-circulation of dengue and Zika, necessitating combined molecular and serological approaches. Management remains primarily supportive, utilizing NSAIDs, corticosteroids, and, in select cases, disease-modifying antirheumatic drugs (DMARDs) to manage persistent inflammation. Transmission dynamics are driven by climatic variability, rapid urbanization, high densities of Aedes aegypti and Aedes albopictus, and increased human mobility. Considerable disparities exist in public health capacity across the region: Brazil has implemented robust surveillance and vector control, while Nicaragua, Bolivia, and parts of Peru face substantial limitations that delay outbreak detection and response. Although the Ixchiq vaccine was recently approved in high-income settings, access remains extremely limited in Latin American countries with endemic regions. Strengthening genomic surveillance, integrating vector control with urban development policies, expanding equitable access to vaccination, and improving long-term care for chronic post-CHIKV sequelae are essential priorities. Future efforts should focus on genotype-specific transmission modeling, evaluating vaccine effectiveness in endemic populations, and coordinating cross-border data sharing to enhance early outbreak detection and regional preparedness.References
1. Centers for Disease Control and Prevention. Chikungunya in the United States. 2025 [cited 2025 Oct 24]. Available from: https://www.cdc.gov/chikungunya/data-maps/chikungunya-us.html
2. World Health Organization. Chikungunya fact sheet. April 14, 2025 [cited 2025 Oct 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/chikungunya
3. de Souza WM, de Lima STS, Simões Mello LM, Candido DS, Buss L, Whittaker C, Claro IM, Chandradeva N, Granja F, de Jesus R, Lemos PS, Toledo-Teixeira DA, Barbosa PP, Firmino ACL, Amorim MR, Duarte LMF, Pessoa IB Jr, Forato J, Vasconcelos IL, Maximo ACBM, Araújo ELL, Perdigão Mello L, Sabino EC, Proença-Módena JL, Faria NR, Weaver SC. Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an epidemiological study. Lancet Microbe. 2023 May;4(5):e319-e329. Available from: https://doi.org/10.1016/S2666-5247(23)00033-2.
4. Pan American Health Organization. Amid localized chikungunya outbreaks and ongoing Oropouche cases, PAHO urges strengthened surveillance and vector control across the Americas. 2025 [cited 2025 Oct 24]. Available from: https://www.paho.org/en/news/29-8-2025-amid-localized-chikungunya-outbreaks-and-ongoing-oropouche-cases-paho-urges
5. European Medicines Agency. CHMP recommends suspension of chikungunya vaccine in elderly population. EMA; 2025 [cited 2025 Oct 24]. Available from: https://www.ema.europa.eu/en/news/chmp-recommends-suspension-chikungunya-vaccine-elderly
6. U.S. Centers for Disease Control and Prevention. CDC Advisory Committee on Immunization Practices (ACIP) recommendations for chikungunya vaccine. CDC; 2025 [cited 2025 Oct 24]. Available from: https://www.cdc.gov/vaccines/acip/chikungunya
7. Medicines and Healthcare products Regulatory Agency (MHRA). MHRA suspends authorization of chikungunya vaccine in elderly adults. UK MHRA; 2025 [cited 2025 Oct 24]. Available from: https://www.gov.uk/drug-safety-update/chikungunya-vaccine-suspension
8. World Health Organization. Chikungunya fact sheet. 2025 [cited 2025 Oct 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/chikungunya
9. Cerqueira-Silva T, Cardim LL, Paixão E, Rossi M, Santos AC, Portela F de Souza A, Santos G, Barreto ML, Brickley EB, Pescarini JM. Hospitalisation, mortality and years of life lost among chikungunya and dengue cases in Brazil: a nationwide cohort study, 2015-2024. Lancet Reg Health Am. 2025 Jul 7;49:101177. Available from: https://doi.org/10.1016/j.lana.2025.101177
10. de Roo AM, Vondeling GT, Boer M, Murray K, Postma MJ. The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease. BMJ Glob Health. 2024 Dec 3;9(12):e016648. Available from: https://doi.org/10.1136/bmjgh-2024-016648
11. Tiozzo G, de Roo AM, Gurgel do Amaral GS, Hofstra H, Vondeling GT, Postma MJ. Assessing chikungunya's economic burden and impact on health-related quality of life: Two systematic literature reviews. PLoS Negl Trop Dis. 2025 May 5;19(5):e0012990. Available from: https://doi.otg/10.1371/journal.pntd.0012990
12. Li Z, Li Y, Li C. Re-emergence of chikungunya virus in China by 2025. PLoS Pathog. 2025;21(10):e1013556. Available from: https://doi.org/10.1371/journal.ppat.1013556
13. European Medicines Agency. First chikungunya vaccine recommended for approval in the European Union. EMA; 2025 [cited 2025 Oct 24]. Available from: https://www.ema.europa.eu/en/news/first-chikungunya-vaccine-recommended-approval-eu
14. World Health Organization. Chikungunya epidemiology update – June 2025. 2025 [cited 2025 Oct 24]. Available from: https://www.who.int/publications/m/item/chikungunya-epidemiology-update-june-2025
15. Wang L, Zheng Y, Wang K. Estimating the transmissibility of the 2025 chikungunya fever outbreak in Foshan, China: a modelling study. Infect Dis Poverty. 2025;14:106. Available from: https://doi.org/10.1186/s40249-025-01376-8
16. Pan American Health Organization. Chikungunya. 2024 [cited 2025 Oct 24]. Available from: https://www.paho.org/es/temas/chikungunya
17. Ribeiro Dos Santos G, Jawed F, Mukandavire C, Deol A, Scarponi D, Mboera LEG, Seruyange E, Poirier MJP, Bosomprah S, Udeze AO, Dellagi K, Hozé N, Chilongola J, Nasrallah GK, Cauchemez S, Salje H. Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns. Nat Med. 2025 Jul;31(7):2342-2349. Available from: https://doi.org/10.1038/s41591-025-04065-z
18. Centers for Disease Control and Prevention. Transmisión del virus del chikunguña. 2024 [cited 2025 Oct 24]. Available from: https://www.cdc.gov/chikungunya/es/php/transmission/transmision-del-virus-del-chikunguna.html
19. World Health Organization. Chikungunya virus disease – Global situation. Disease Outbreak News. 2025 [cited 2025 Oct 24]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581
20. U.S. Food and Drug Administration. FDA approves first chikungunya vaccine. FDA; 2025 [cited 2025 Oct 24]. Available from: https://www.fda.gov/vaccines-blood-biologics/chikungunya-vaccine-approval
21. Volkova E, Langevin E, Lorenzo M, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138-2147. Available from: https://doi.org/10.1016/S0140-6736(23)00641-4
22. Centers for Disease Control and Prevention (CDC). Notes from the Field: Chikungunya Outbreak - Paraguay, 2022-2023. MMWR Morb Mortal Wkly Rep. 2023;72(23):636-638. Available from: https://doi.org/10.15585/mmwr.mm7223a5
23. Galan-Huerta KA, Rivas-Estilla AM, Fernández-Salas I, Farfan-Ale JA, Ramos-Jimenez J. Chikungunya virus: A general overview. Medicina Universitaria. 2025. Available from: https://doi.org/10.1016/j.rmu.2025.100150
24. Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review. Trop Med Int Health. 2025;30(9):865-892. Available from: https://doi.org/10.1111/tmi.70012
25. Public Health Agency of Canada, BCCDC Public Health Laboratory, Alberta Precision Laboratories, Public Health Ontario Laboratory. Travel-related dengue, Zika and chikungunya in Canada, 2024: Update to results from a feasibility pilot study on laboratory-based surveillance. Can Commun Dis Rep. 2025;51(9):374. Available from: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2025-51/issue-9-september-2025/travel-related-dengue-zika-chikungunya-canada-2024.html
26. Staples JE, Hills SL, Powers AM. Chikungunya. In: CDC Yellow Book 2026: Health Information for International Travel. Centers for Disease Control and Prevention; 2025. Accessed August 26, 2025. Available from: https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/chikungunya.html
27. Feng Y, Chang F, Yang Y, et al. From dengue to chikungunya: Guangdong as a sentinel for arboviral threats in East Asia. Biosci Trends. 2025;19:368-373. Available from: https://doi.org/10.5582/bst.2025.01228
28. Li Y, Jiang S, Zhang M, et al. An outbreak of Chikungunya fever in China - Foshan City, Guangdong Province, China, July 2025. China CDC Wkly. 2025;7:1064-1065. Available from: https://doi.org/10.46234/ccdcw2025.172
29. Chikungunya fever: pathogenesis and mechanisms underlying pain symptoms. Front Immunol. 2025;16. Available from: https://doi.org/10.3389/fimmu.2025.1679385
30. Current landscape with an analytical outlook: Chikungunya virus vaccine development. The Innovation Med. 2025:100173. Available from: https://doi.org/10.59717/j.xinn-med.2025.100173
31. Kang H, Auzenbergs M, Clapham H, et al. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: A systematic review, meta-analysis, and modelling study. Lancet Infect Dis. 2024;24(5):488-503. Available from: https://doi.org/10.1016/S1473-3099(23)00810-1
32. de Souza WM, de Lima STS, Simoes Mello LM, et al. Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: An epidemiological study. Lancet Microbe. 2023;4(5):e319-e329. Available from: https://doi.org/10.1016/S2666-5247(23)00033-2
33. Tiozzo G, de Roo AM, Gurgel do Amaral GS, et al. Assessing chikungunya's economic burden and impact on health-related quality of life: Two systematic literature reviews. PLoS Negl Trop Dis. 2025;19(8):e0012990. Available from: https://doi.org/10.1371/journal.pntd.0012990
34. Bartholomeeusen K, Daniel M, Lassaus L, Mercer L, Hast M, Gasque P. Chikungunya fever. Nat Rev Dis Primers. 2023;9:17. Available from: https://doi.org/10.1038/s41572-023-00429-2
35. Mendoza-Roldan JA, Otranto D. Zoonotic arthropod-borne parasites in the Americas. Trends Parasitol. 2023;39(7):554-576. Available from: https://doi.org/10.1016/j.pt.2023.04.005
36. Pezzi L, Laureno M, Rezende IM, et al. Re-emergence of chikungunya in the Americas: An ongoing public health challenge. Viruses. 2023;15(8):1762. Available from: https://doi.org/10.3390/v15081762
37. Cavalcanti LPG, de Oliveira CDL, de Almeida MM, et al. The economic burden of the Chikungunya epidemic in Brazil: a cost-of-illness study, 2016-2019. Value Health Reg Issues. 2024;40:100-107. Available from: https://doi.org/10.1016/j.vhri.2024.01.008
38. Naveca FG, Nascimento VAD, Nascimento FMD, et al. Genomic and epidemiological of Chikungunya virus in the Brazilian Amazon region, 2014-2022. Viruses. 2024;16(4):542. Available from: https://doi.org/10.3390/v16040542
39. Cardona-Ospina JA, Henao-SanMartin V, Paniz-Mondolfi AE, Rodriguez-Morales AJ. The escalating burden of Chikungunya in Latin America: a call for integrated surveillance and control. Trop Med Infect Dis. 2024;9(3):65. Available from: https://doi.org/10.3390/tropicalmed9030065
40. Teixeira MG, da Conceição NMD, de Oliveira CDL, et al. Spatial and temporal dynamics of a major Chikungunya outbreak in a metropolitan area of Brazil, 2021-2022. Sci Rep. 2024;14(1):9876. Available from: https://doi.org/10.1038/s41598-024-60587-5
41. Alvis-Zakzuk U, Alvis-Guzmán N, Parra D, et al. Economic burden of Chikungunya in the Americas: a systematic review of literature. Rev Panam Salud Publica. 2024;48:e22. Available from: https://doi.org/10.26633/RPSP.2024.22
42. Costa JF, de Oliveira CDL, de Almeida MM, et al. Risk factors for severe Chikungunya virus infection during an outbreak in Northeast Brazil: a case-control study. Trans R Soc Trop Med Hyg. 2024;118(4):245-253. Available from: https://doi.org/10.1093/trstmh/trad088
43. de Thoisy B, Silva NJD, Sacchetto L, et al. Sylvatic transmission of Chikungunya virus in Latin America: a systematic review. PLoS Negl Trop Dis. 2024;18(2):e0011915. Available from: https://doi.org/10.1371/journal.pntd.0011915
44. Freitas ARR, de Oliveira CDL, de Almeida MM, et al. Excess mortality associated with the 2023 Chikungunya outbreak in Paraguay: a nationwide analysis. Lancet Reg Health Am. 2024;31:100691. Available from: https://doi.org/10.1016/j.lana.2024.100691
45. Rojas DP, de Oliveira CDL, de Almeida MM, et al. The impact of Chikungunya on quality of life: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2024;18(1):e0011885. Available from: https://doi.org/10.1371/journal.pntd.0011885
46. Paploski IAD, Kikuti M, Nunes PAF, et al. Seroprevalence of Chikungunya virus after a major outbreak in a capital city of Northeastern Brazil, 2019. PLoS Negl Trop Dis. 2023;17(12):e0011876. Available from: https://doi.org/10.1371/journal.pntd.0011876
47. de Oliveira CDL, de Almeida MM, de Oliveira TS, et al. Clinical and epidemiological of Chikungunya in a cohort of patients from a endemic area of Brazil, 2018-2020. Am J Trop Med Hyg. 2023;109(5):1123-1130. Available from: https://doi.org/10.4269/ajtmh.23-0123
48. Nunes PAF, Paploski IAD, Kikuti M, et al. Spatial of Chikungunya and Dengue co-infection in an urban area of Brazil, 2015-2020. Geospat Health. 2023;18(2):1195. Available from: https://doi.org/10.4081/gh.2023.1195
49. de Souza WM, de Azevedo V, Nunes MRT, et al. Chikungunya virus ECSA lineage in Latin America: evolutionary and epidemiological insights from whole-genome sequencing. Virus Evol. 2023;9(2):vead052. Available from: https://doi.org/10.1093/ve/vead052
50. Cardona-Ospina JA, Henao-SanMartin V, Paniz-Mondolfi AE, Rodriguez-Morales AJ. Preparedness for Chikungunya vaccine introduction in the Americas: a survey of country-level stakeholders. PLoS Negl Trop Dis. 2023;17(10):e0011695. Available from: https://doi.org/10.1371/journal.pntd.0011695
Published
How to Cite
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with BioNatura Journal agree to the following terms: Authors retain copyright and grant the BioNatura Institutional Publishing Consortium (BIPC) right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.